November 21, 2011
CSIMC General Assembly on Nov. 18 Novartis Pharma’s Ilaris (canakinumab), a treatment for cryopyrin-associated period syndrome (CAPS) whose NHI price listing was delayed by the Central Social Insurance Medical Council (CSIMC; Chuikyo ) on November 16 due to an insufficient...read more